PetVivo Holdings: Director Change — Michael K. Handley Appointed

What Happened
PetVivo Holdings, Inc. announced that director Joseph Jasper resigned from the Board effective September 22, 2026; his resignation was not due to any disagreement with the Company. The Board immediately appointed Michael K. Handley to fill the vacancy, keeping the Board size at six directors. Mr. Handley will serve until the next annual shareholder meeting and until his successor is elected and qualified (or earlier death, resignation or removal).

Key Details

• Joseph Jasper resigned effective September 22, 2026; resignation not due to disagreement with the Company.
• Michael K. Handley appointed effective September 22, 2026; will serve as a non-employee director until the next annual meeting.
• Board size remains six directors.
• Handley background highlights: over 25 years in life sciences; helped raise >$700 million in public/private capital; involved in transactions exceeding $4 billion; recent roles include CEO of Valion Bio (Mar–Aug 2026) and senior leadership at Statera Biopharma, Immune Therapeutics, Armis Biopharma, Genentech, Amgen and others.
• Compensation: Handley will receive the Company’s standard non-employee director compensation, prorated for his period of service; no special arrangements or related-party transactions reported.

Why It Matters
Board changes can affect company strategy, oversight and investor confidence. PetVivo replaced Jasper with an experienced life‑sciences executive with a track record in capital raising, regulatory affairs and commercialization, which the Board cited as material to its decision. For investors, the change signals the Board’s continued focus on bringing industry and commercialization experience to guide PetVivo’s development; there are no disclosed disagreements or related-party issues tied to the change.